CCN2 and gastric cancer: Wei Kang, et al. [24] have reported that miR-375 inhibited tumor growth in vitro and in vivo, and its targets, YAP1, TEAD4 and CTGF, could partially abolish the tumor-suppressive effect in gastric cancer.